BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 12823348)

  • 1. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy.
    Lachmann HJ; Gallimore R; Gillmore JD; Carr-Smith HD; Bradwell AR; Pepys MB; Hawkins PN
    Br J Haematol; 2003 Jul; 122(1):78-84. PubMed ID: 12823348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum levels of free light chain before and after chemotherapy in primary systemic AL amyloidosis.
    Matsuda M; Yamada T; Gono T; Shimojima Y; Ishii W; Fushimi T; Sakashita K; Koike K; Ikeda S
    Intern Med; 2005 May; 44(5):428-33. PubMed ID: 15942088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative analysis of serum free light chains. A new marker for the diagnostic evaluation of primary systemic amyloidosis.
    Abraham RS; Katzmann JA; Clark RJ; Bradwell AR; Kyle RA; Gertz MA
    Am J Clin Pathol; 2003 Feb; 119(2):274-8. PubMed ID: 12579999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine.
    Palladini G; Russo P; Bosoni T; Verga L; Sarais G; Lavatelli F; Nuvolone M; Obici L; Casarini S; Donadei S; Albertini R; Righetti G; Marini M; Graziani MS; Melzi D'Eril GV; Moratti R; Merlini G
    Clin Chem; 2009 Mar; 55(3):499-504. PubMed ID: 19131635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amino acid sequence homology of monoclonal serum free light chain dimers and tissue deposited light chains in AL amyloidosis: a pilot study.
    Goldis R; Kaplan B; Arad M; Dispenzieri A; Dasari S; Kukuy OL; Simon AJ; Dori A; Shavit-Stein E; Ziv T; Murray D; Kourelis T; Gertz MA; Dominissini D; Magen H; Muchtar E
    Clin Chem Lab Med; 2024 Feb; 62(3):464-471. PubMed ID: 37747270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays.
    Palladini G; Jaccard A; Milani P; Lavergne D; Foli A; Bender S; Lavatelli F; Bosoni T; Valentini V; Pirolini L; Ferraro G; Basset M; Russo F; Nuvolone M; Albertini R; Cogne M; Merlini G
    Clin Chem Lab Med; 2017 Oct; 55(11):1734-1743. PubMed ID: 28343171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation.
    Dispenzieri A; Lacy MQ; Katzmann JA; Rajkumar SV; Abraham RS; Hayman SR; Kumar SK; Clark R; Kyle RA; Litzow MR; Inwards DJ; Ansell SM; Micallef IM; Porrata LF; Elliott MA; Johnston PB; Greipp PR; Witzig TE; Zeldenrust SR; Russell SJ; Gastineau D; Gertz MA
    Blood; 2006 Apr; 107(8):3378-83. PubMed ID: 16397135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum-free light-chain analysis in diagnosis and management of multiple myeloma and related conditions.
    Milani P; Palladini G; Merlini G
    Scand J Clin Lab Invest Suppl; 2016; 245():S113-8. PubMed ID: 27467897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term follow-up of plasma cells in bone marrow and serum free light chains in primary systemic AL amyloidosis.
    Yoshida T; Matsuda M; Katoh N; Tazawa K; Shimojima Y; Gono T; Ishii W; Nakazawa Y; Sakashita K; Koike K; Yamada T; Ikeda S
    Intern Med; 2008; 47(20):1783-90. PubMed ID: 18854629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isolation and biochemical characterization of plasma monoclonal free light chains in amyloidosis and multiple myeloma: a pilot study of intact and truncated forms of light chains and their charge properties.
    Kaplan B; Ramirez-Alvarado M; Dispenzieri A; Zeldenrust SR; Leung N; Livneh A; Gallo G
    Clin Chem Lab Med; 2008; 46(3):335-41. PubMed ID: 18254719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic and prognostic utility of the serum free light chain assay in patients with AL amyloidosis.
    Morris KL; Tate JR; Gill D; Kennedy G; Wellwood J; Marlton P; Bird R; Mills AK; Mollee P
    Intern Med J; 2007 Jul; 37(7):456-63. PubMed ID: 17547724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein.
    Gillmore JD; Lovat LB; Persey MR; Pepys MB; Hawkins PN
    Lancet; 2001 Jul; 358(9275):24-9. PubMed ID: 11454373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative serum free light chain assay in the diagnostic evaluation of AL amyloidosis.
    Akar H; Seldin DC; Magnani B; O'Hara C; Berk JL; Schoonmaker C; Cabral H; Dember LM; Sanchorawala V; Connors LH; Falk RH; Skinner M
    Amyloid; 2005 Dec; 12(4):210-5. PubMed ID: 16399645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel approach for the purification and proteomic analysis of pathogenic immunoglobulin free light chains from serum.
    Lavatelli F; Brambilla F; Valentini V; Rognoni P; Casarini S; Di Silvestre D; Perfetti V; Palladini G; Sarais G; Mauri P; Merlini G
    Biochim Biophys Acta; 2011 Mar; 1814(3):409-19. PubMed ID: 21215335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum-free light-chain assay: clinical utility and limitations.
    Bhole MV; Sadler R; Ramasamy K
    Ann Clin Biochem; 2014 Sep; 51(Pt 5):528-42. PubMed ID: 24489083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [AL-amyloidosis and its treatment by eliminating the precursor protein].
    Verbeek DE; Hazenberg BP; Jager PL; Kremer Hovinga TK
    Ned Tijdschr Geneeskd; 2007 Sep; 151(37):2021-6. PubMed ID: 17929708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum free light chain analysis may miss monoclonal light chains that urine immunofixation electrophoreses would detect.
    Shaheen SP; Levinson SS
    Clin Chim Acta; 2009 Aug; 406(1-2):162-6. PubMed ID: 19410572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the serum-free light chain test in untreated patients with AL amyloidosis.
    Bochtler T; Hegenbart U; Heiss C; Benner A; Cremer F; Volkmann M; Ludwig J; Perz JB; Ho AD; Goldschmidt H; Schonland SO
    Haematologica; 2008 Mar; 93(3):459-62. PubMed ID: 18287137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of the Serum Free Light Chain Assay in the Diagnosis of Light Chain Amyloidosis in Patients With Heart Failure.
    Chang IC; Dispenzieri A; Scott CG; Lin G; Jaffe AS; Klarich KW; Grogan M
    Mayo Clin Proc; 2019 Mar; 94(3):447-454. PubMed ID: 30718069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis.
    Kumar SK; Dispenzieri A; Lacy MQ; Hayman SR; Buadi FK; Zeldenrust SR; Tan T; Sinha S; Leung N; Kyle RA; Rajkumar SV; Gertz MA
    Am J Hematol; 2011 Mar; 86(3):251-5. PubMed ID: 21328431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.